5,6-dihydroindolizine | 34192-80-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 5,6-dihydroindolizine
• 英文别名: 5,6-dihydro-indolizine；5,6-Dihydro-indolizin；5,6-Dihydroindolizin
• CAS: 34192-80-8
• 化学式: C₈H₉N
• 分子量: 119.166
• InChiKey: FQKOGTWNFJGTLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  吲嗪 在 乙醇 、 sodium 作用下， 生成 5,6-dihydroindolizine
  参考文献：
  名称：

  Cliff et al., Journal of the Chemical Society C: Organic, 1971, p. 3426

  摘要：

  DOI：

文献信息

• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150368278A1

  公开（公告）日：2015-12-24

  The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

  本发明提供了由任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物及其药学上可接受的组合物所包含的范围，或其亚属所包含的范围。本发明还提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来治疗FAAH介导的疾病、紊乱或症状的方法。此外，本发明提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来抑制FAAH的方法。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：SELCIA LTD

  公开号：WO2010029364A1

  公开（公告）日：2010-03-18

  The present invention relates to new therapeutic and prophylactic applications of known compounds of general formula (Ia), novel compounds of formula (1a) wherein R3 is methyl, and to compositions comprising them, useful as a medication for the topical therapeutic and prophylactic treatment of dermatological and ophthalmic disorders, rheumatoid arthritis and osteoarthritis.

  本发明涉及一般式(Ia)已知化合物的新治疗和预防应用，一般式(1a)中R3为甲基的新化合物，以及包含它们的组合物，用作治疗和预防皮肤病和眼科疾病、类风湿性关节炎和骨关节炎的局部药物。
• Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof
  申请人：——

  公开号：US20040122002A1

  公开（公告）日：2004-06-24

  The present invention relates to fused pyrrole compounds of the formula 1. 1 in which at least one of the radicals R1, R2, R3 is 4-sulphur-substituted phenyl. These compounds are in particular pyrrolizines, indolizines and heteroanalogues having selective inhibitory action on isoenzyme-2 of prostaglandin H synthase (COX-2). The invention also relates to pharmaceutical compositions which contain these compounds; and the use of these compounds for the treatment of disorders of the rheumatic type.

  本发明涉及式1.1的融合吡咯化合物，其中至少一个基团R1、R2、R3是4-硫代取代苯基。这些化合物特别是吡咯啉、吲哚啉和杂环类似物，具有对前列腺素H合成酶同工酶2的选择性抑制作用。本发明还涉及含有这些化合物的药物组合物；以及使用这些化合物治疗风湿性疾病的方法。
• Compounds
  申请人：Jones Andrew

  公开号：US20110184011A1

  公开（公告）日：2011-07-28

  The present invention relates to new therapeutic and prophylactic applications of known compounds of general formula (Ia), novel compounds of formula (Ia) wherein R3 is methyl, and to compositions comprising them, useful as a medication for the topical therapeutic and prophylactic treatment of dermatological and ophthalmic disorders, rheumatoid arthritis and osteoarthritis.

  本发明涉及已知通式（Ia）化合物的新治疗和预防应用，通式（Ia）中的新化合物为R3为甲基的化合物，以及包含它们的组合物，作为用于治疗皮肤病和眼科疾病、类风湿性关节炎和骨关节炎的局部治疗和预防药物。
• Annellated pyrrole compounds for cancer management
  申请人：MERCKLE GMBH

  公开号：EP1884239A1

  公开（公告）日：2008-02-06

  The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone) salts or derivatives thereof, for cancer management, and in general to the use of a compound of Formula (I): wherein the variables have the meanings given in the present description, for the prevention and/or treatment of neoplasia, in particular neoplasia selected from the group consisting of papilloma, carcinoma, adenoma and adenocarcinoma, e. g. human airway or colorectal carcinoma, preferably fast-growing, multidrug resistant and/or COX-2 negative neoplasia. The invention further relates to pharmaceutical compositions for the aforesaid purposes, comprising annellated pyrrole compounds and in particular ML3000 (licofelone), optical isomers, salts or derivatives thereof, as well as to a method of treating and/or preventing neoplasia and/or restoring the ability to undergo apoptosis in a cell having lost the same. This treatment ameliorates, diminishes, actively treats, reverses or prevents any disease related to insufficient apoptosis, in particular neoplasia, and it may be combined with irradiation, heating and treatment with a cytotoxic agent for preventive and/or curative purposes.

  本发明涉及环状吡咯化合物，特别是 ML3000（利可非龙）的用途 盐或其衍生物在癌症治疗中的应用，一般涉及式（I）化合物的应用： 其中各变量的含义见本说明书、 用于预防和/或治疗肿瘤，特别是从乳头状瘤、癌、腺瘤和腺癌组成的组中选出的肿瘤，例如人类气道癌或结肠直肠癌，最好是快速生长、耐多药和/或 COX-2 阴性的肿瘤。 本发明还涉及用于上述目的的药物组合物，包括环状吡咯化合物，特别是 ML3000（利可非龙）、其光学异构体、盐或衍生物，以及治疗和/或预防肿瘤和/或恢复细胞凋亡能力的方法。 这种治疗方法可以改善、减轻、积极治疗、逆转或预防任何与细胞凋亡不足有关的疾病，特别是肿瘤，它可以与辐照、加热和细胞毒剂治疗相结合，以达到预防和/或治疗的目的。